Recent News

• 08.05.2026 - Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
• 08.04.2026 - Lucid Diagnostics to Participate in Upcoming Investor Conferences
• 07.30.2026 - Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
• 04.30.2026 - Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
• 04.24.2026 - Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
• 04.23.2026 - Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
• 04.09.2026 - Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
• 03.26.2026 - Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• 03.12.2026 - Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
• 01.21.2026 - Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®

Recent Filings

• 06.24.2026 - 8-K Current report
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.14.2026 - EX-99.1 EX-99.1
• 05.14.2026 - 8-K Current report
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.30.2026 - ARS Annual Report to Security Holders
• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.24.2026 - 3/A Initial statement of beneficial ownership of securities
• 04.24.2026 - 8-K Current report